# US 2016/0354498 A1 · Imaging and therapy of virus-associated tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354498 A1
- Document ID: US20160354498A1
- Status: Published application
- Kind: A1
- Application number: 15/072,896
- Filed: 2016-03-17
- Published: 2016-12-08
- Earliest claimed: 2007-04-10
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Martin G. Pomper; Richard Ambinder; Jun O. Liu; Curtis R. Chong; Jianmeng Chen
- Web page: https://patentgrep.com/patent/US20160354498A1

## CPC

- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/42: Oxazoles
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/22: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.

## Claims

### Claim at position 1

-31. (canceled)

### Claim 32

A method for detecting an infection associated neoplasia in a subject, the method comprising administering to the subject an effective amount of a viral lytic induction agent and a radiolabeled analog of 2′-deoxy-5-iodo-I-beta-D-arabinofuranosyluracil (FIAU), and visualizing the neoplasia.

### Claim at position 3

-37. (canceled)

### Claim 38

A method for selecting a therapy for a subject having an infection associated neoplasia, the method comprising administering to the subject an effective amount of a viral lytic induction agent and a radiolabeled analog of 2′-deoxy-5-iodo-I-beta-D-arabinofuranosyluracil (FIAU); and
detecting the presence or absence of lytic induction in the subject, wherein an increase in lytic induction identifies a subject as amenable to treatment with a lytic induction agent and enzyme-targeted radiation therapy.

### Claim at position 5

-40. (canceled)

### Claim 41

A method for killing a neoplastic cell infected with a virus or bacteria, the method comprising contacting the cell with an effective amount of a viral lytic induction agent and a radiolabeled analog of 2′-deoxy-5-iodo-I-beta-D-arabinofuranosyluracil (FIAU).

### Claim at position 7

-63. (canceled)
